TOKYO, Mar 24 (Pulse News Wire) – Noile-Immune Biotech Inc. (4893.T) announced the initiation of dosing for its first patient in the Phase I clinical trial of NIB103, a PRIME CAR-T cell therapy targeting Mesothelin-expressing solid tumors.
The trial, aimed at evaluating safety and efficacy in patients with advanced or metastatic solid tumors unresponsive to standard treatments, will enroll up to 30 cases. NIB103 targets Mesothelin, a tumor antigen found in cancers such as breast, colorectal, ovarian, and pancreatic cancer. The PRIME technology enhances CAR-T cells to produce IL-7 and CCL19, promoting T-cell proliferation and survival while improving their ability to migrate to tumor sites.
In September 2024, the company entered into a collaboration agreement with Takara Bio Inc. for joint development of the trial in Japan. The impact on the company's fiscal year ending December 2026 is expected to be minor, but Noile-Immune will promptly disclose any significant developments.
🟢 Confidence: High AI-translated content.